MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202641051156 A) filed by Saveetha Institute Of Medical And Technical Sciences on April 22, 2026, for Multimodal Graphene -Based Intraoral Electronic Tattoo Platform For Continuous Non- Invasive Monitoring Of Oral Cancer Microenvironment.
Inventors include Soundharya Manogaran; Ramya Ramadoss; and Deepak Nallaswamy Veeraiyan.
The application for the patent was published on June 19, 2026, under issue no. 25/2026.
Abstract: Abstract The present invention relates to a flexible intraoral biosensing platform for continuous monitoring of biomarkers associated with oral squamous cell carcinoma (OSCC). More particulRrly, the invention discloses a transparent, ultrathin graphene-based mucosal electronic tattoo designed to adhere to wet buccal mucosa for extended durations to enable real-time multimodal sensing. The device comprises a mucoadhesive hydrogel base layer, a patterned graphene sensing film, and a protective nanolayer configured to resist saliva exposure and biofouling while permitting analyte diffusion. The graphene sensing film incorporates a plurality ofmicroelectrodes configured for electrical impedance mapping, electrochemical detection of inflammatory cytokines and proteases, and microvascular perfusion monitoring associated with early tumor microenvironment changes. Cytokine sensing is achieved through functionalized graphene probe pads capable of detecting biomarkers such as IL-6, TNF-a, and MMP-9 in saliva at low concentrations. The tattoo is designed to conform to soft oral tissues with a total thickness ofless than 30 j.tm and can maintain adhesion for approximately 6 to 72 hours under normal oral activity. The system operates through passive wireless power harvesting and data transmission using near-field communication (NFC) or inductive coupling, enabling continuous or intermittent data acquisition via an external reader and mobile interface. By integrating biochemical and biophysical sensing modalities within a single intraoral platform, the invention enables continuous, non-invasive monitoring of early pathological changes associated with oral cancer, thereby facilitating improved screening, risk stratification, and disease surveillance.
Disclaimer: Curated by HT Syndication.
